Merck has announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), as well as the newly approved subcutaneous formulation KEYTRUDA QLEx™, in combination with WELIREG® (belzutifan) for the adjuvant treatment of certain patients with renal cell carcinoma (RCC), the most common form of kidney cancer.
The approval marks an important advancement for patients who have undergone surgery for kidney cancer but remain at a high risk of disease recurrence. By combining immunotherapy with a targeted treatment approach, the regimen is designed to reduce the likelihood of cancer returning after surgery.
The FDA’s decision was supported by findings from a late-stage clinical trial that evaluated the effectiveness of the combination in patients with clear-cell renal cell carcinoma who had undergone nephrectomy and were considered at increased risk for recurrence. Study results demonstrated a significant improvement in disease-free survival compared with placebo, indicating that the treatment helped patients remain cancer-free for a longer period following surgery.
KEYTRUDA, one of the world's most widely used immunotherapies, works by helping the immune system recognize and attack cancer cells. WELIREG, meanwhile, targets hypoxia-inducible factor-2 alpha (HIF-2α), a protein that plays a key role in the growth and survival of certain kidney cancer cells. Experts believe the combination provides a complementary approach by activating the body's immune response while simultaneously disrupting cancer-driving pathways.
The approval also includes KEYTRUDA QLEx, a newer subcutaneous version of pembrolizumab administered under the skin. The formulation is expected to offer patients and healthcare providers greater flexibility and potentially shorter treatment administration times compared with traditional intravenous infusion.
Kidney cancer remains one of the most common cancers worldwide, with thousands of new cases diagnosed each year. Although surgery is often successful in removing localized tumors, many patients face the ongoing risk of recurrence, creating a need for effective adjuvant treatment options.
Merck stated that the approval reinforces its commitment to advancing cancer care through innovative therapies and combination strategies. The company continues to evaluate pembrolizumab-based treatments across multiple tumor types and stages of disease.
Oncology specialists say the new approval provides another important option for eligible kidney cancer patients seeking to reduce the risk of recurrence after surgery and may help further improve long-term outcomes in the adjuvant treatment setting.
